Evidence map›Paper›PMID 18356408›Full record

ArticleDiabetes2008

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

Songping Han, Deborah L Hagan, Joseph R Taylor, Li Xin, Wei Meng, Scott A Biller, John R Wetterau, William N Washburn, Jean M Whaley

3 registry-linked trialsOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetes, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 139 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 3 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02694263 phase4completedstarted 2016, after this paper: background citation

A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study

Ran2016Enrolled25Registered outcomes32Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsCanagliflozin, Gliclazide, Glimepiride, Pioglitazone, Repaglinide
PMID 24373063PMID 23564919PMID 26203064PMID 23782529PMID 22492586PMID 24026211PMID 23464594PMID 23279307PMID 24073995PMID 16980531PMID 17805082PMID 17925461other papers from this trial
Open the trial in the graph
NCT00924053 phase1completednot on this mapstarted 2009, after this paper: background citation

A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of EGT0001474 in Subjects With Type 2 Diabetes

TypeinterventionalSponsorTheracosRan2009 to 2009Enrolled24ConditionsDiabetes Mellitus Type 2ArmsEGT0001474, Placebo
NCT01377844 phase2completednot on this mapstarted 2011, after this paper: background citation

Efficacy and Safety of EGT0001442 Compared With Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Diet and Exercise and up to One Oral Anti-diabetes Agent

TypeinterventionalSponsorTheracosRan2011 to 2013Enrolled288ConditionsDiabetes MellitusArmsEGT0001442, Placebo
3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 3 syntheses or guidelines pooled it, 417 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1-Mediated Glucotoxic Stress in Diabetic Kidney Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Songping HanMetabolic Diseases Biology, Bristol-Myers Squibb Research and Development, Princeton, New Jersey, USA.
Deborah L Hagan
Joseph R Taylor
Li Xin
Wei Meng
Scott A Biller
John R Wetterau
William N Washburn
Jean M Whaley
Bristol-Myers Squibb (United States) · USNovartis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe inhibition of gut and renal sodium-glucose cotransporters (SGLTs) has been proposed as a novel therapeutic approach to the treatment of diabetes. We have identified dapagliflozin as a potent and selective inhibitor of the renal sodium-glucose cotransporter SGLT2 in vitro and characterized its in vitro and in vivo pharmacology. RESEARCH DESIGN AND

methodsCell-based assays measuring glucose analog uptake were used to assess dapagliflozin's ability to inhibit sodium-dependent and facilitative glucose transport activity. Acute and multi-dose studies in normal and diabetic rats were performed to assess the ability of dapagliflozin to improve fed and fasting plasma glucose levels. A hyperinsulinemic-euglycemic clamp study was performed to assess the ability of dapagliflozin to improve glucose utilization after multi-dose treatment.

resultsDapagliflozin potently and selectively inhibited human SGLT2 versus human SGLT1, the major cotransporter of glucose in the gut, and did not significantly inhibit facilitative glucose transport in human adipocytes. In vivo, dapagliflozin acutely induced renal glucose excretion in normal and diabetic rats, improved glucose tolerance in normal rats, and reduced hyperglycemia in Zucker diabetic fatty (ZDF) rats after single oral doses ranging from 0.1 to 1.0 mg/kg. Once-daily dapagliflozin treatment over 2 weeks significantly lowered fasting and fed glucose levels at doses ranging from 0.1 to 1.0 mg/kg and resulted in a significant increase in glucose utilization rate accompanied by a significant reduction in glucose production.

conclusionsThese data suggest that dapagliflozin has the potential to be an efficacious treatment for type 2 diabetes.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsAdipocytesAnimalsBenzhydryl CompoundsBlood GlucoseCell LineCloning, MolecularGlucoseGlucosidesHumansRatsRats, ZuckerReference ValuesSodium-Glucose Transporter 1Sodium-Glucose Transporter 2Sodium-Glucose Transport ProteinsBenzhydryl CompoundsBlood GlucosedapagliflozinGlucoseGlucosidesSLC5A1 protein, humanSlc5a1 protein, ratSLC5A2 protein, humanSlc5a2 protein, ratSodium-Glucose Transporter 1Sodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transport Proteins

Identifiers

PMID18356408
OpenAlexW2171786511

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.